Agios Pharmaceuticals AGIO Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's total equity?
- Agios Pharmaceuticals (AGIO) reported total equity of $1.11B in Q1 2026.
- How has Agios Pharmaceuticals's total equity changed year-over-year?
- Agios Pharmaceuticals's total equity decreased by 24.4% year-over-year, from $1.47B to $1.11B.
- What is the long-term trend for Agios Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's total equity has grown at a 24.5% compound annual growth rate (CAGR), from $399.5M to $1.19B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.